Letter to the FDA Urging the Agency Not to Approve the New Drug Application for Sufentanil Sublingual Tablets, a Super-Potent Opioid

View as PDF

View press release

In a letter to the Food and Drugs Administration (FDA), the chair of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee joined three Public Citizen experts in urging the agency to reject Acer Pharmaceuticals’ new drug application for sufentanil sublingual tablets for treatment of moderate-to-severe acute pain in a medically supervised setting. This opioid, which is five to 10 times more potent than fentanyl and 1,000 times more potent than morphine, would be abused and start killing people as soon as it hits the market.

See Public Citizen’s other work on sufentanil tablets.

See Public Citizen’s other work on opioid drug issues.